ArticleEMBO molecular medicine2018
An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors.
Open access · goldAbstract read
In one paragraph
Article in EMBO molecular medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 56 citations in OpenAlex.
- Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment ofJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Trial
- Fc-Dependent Targeting of the GAS6-MERTK Axis With Monoclonal and Bispecific Antibodies Overcomes Drug Resistance Across EGFR Mutations in Exons 19, 20, and 21.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- SOS1 inhibition suppresses the emergence of osimertinib resistance to generate a durable response inScience signaling · 2025Article
- Identification of potent biparatopic antibodies targeting FGFR2 fusion-driven cholangiocarcinoma.The Journal of clinical investigation · 2025Article
- Strategies to Overcome Resistance to Osimertinib in EGFR-Mutated Lung Cancer.International journal of molecular sciences · 2025Review
- A bispecific antibody targeting EGFR and AXL delays resistance to osimertinib.Cell reports. Medicine · 2024Article
- Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models.Scientific reports · 2024Article
- SOS2 modulates the threshold of EGFR signaling to regulate osimertinib efficacy and resistance in lung adenocarcinoma.Molecular oncology · 2024Article
- Article
- SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Resistance of Lung Cancer to EGFR-Specific Kinase Inhibitors: Activation of Bypass Pathways and Endogenous Mutators.Cancers · 2023Review
- SOS2 regulates the threshold of mutantbioRxiv : the preprint server for biology · 2023Article
- HER3-targeted therapeutic antibodies and antibody-drug conjugates in non-small cell lung cancer refractory to EGFR-tyrosine kinase inhibitors.Chinese medical journal pulmonary and critical care medicine · 2023Review
- Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer.Frontiers in immunology · 2023Article
- AXL and Error-Prone DNA Replication Confer Drug Resistance and Offer Strategies to Treat EGFR-Mutant Lung Cancer.Cancer discovery · 2022Article
- Targeting epiregulin in the treatment-damaged tumor microenvironment restrains therapeutic resistance.Oncogene · 2022Article
- HER3 in cancer: from the bench to the bedside.Journal of experimental & clinical cancer research : CR · 2022Review
- An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer.Nature cancer · 2022Article
- Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans.Cell death & disease · 2022Article
- Polyclonal antibody-induced downregulation of HER1/EGFR and HER2 surpasses the effect of combinations of specific registered antibodies.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 3 institutions in 3 countries.
Maicol ManciniDepartment of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
Hilah GalDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
Nadège GaboritDepartment of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
Luigi MazzeoDepartment of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
Donatella RomanielloDepartment of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
Tomer Meir SalameDepartment of Biological Services, Weizmann Institute of Science, Rehovot, Israel.
Moshit LindzenDepartment of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
Georg MahlknechtDepartment of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
Yehoshua EnukaDepartment of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.ORCID 0000-0001-6327-2845
Dominick Ga BurtonDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
Lee RothDepartment of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
Ashish NoronhaDepartment of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
Ilaria MarroccoDepartment of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
Dan AdrekaDepartment of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
Raya Eilam AltstadterDepartment of Veterinary Resources, Weizmann Institute of Science, Rehovot, Israel.
Emilie BousquetOncogenic Pathways in Lung Cancer, Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, Montpellier Cedex 5, France.
Julian DownwardSignal Transduction Laboratory, Francis Crick Institute, London, UK.
Antonio MaraverOncogenic Pathways in Lung Cancer, Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, Montpellier Cedex 5, France.
Valery KrizhanovskyDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.ORCID 0000-0002-3977-5482
Yosef YardenDepartment of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel yosef.yarden@weizmann.ac.il.ORCID 0000-0001-8578-0250
Weizmann Institute of Science · ILInserm · FRInstitute of Cancer Research · GB
Funding
Cancer Research UK 15680
Abstract
Epidermal growth factor receptor (
Indexed as
AcrylamidesAniline CompoundsAntineoplastic Agents, ImmunologicalApoptosisCarcinoma, Non-Small-Cell LungCetuximabDrug Resistance, NeoplasmErbB ReceptorsHumansImmunotherapyIndolesLung NeoplasmsMutationPiperazinesProtein Kinase InhibitorsPyrimidinesAcrylamidesAniline CompoundsAntineoplastic Agents, ImmunologicalCetuximabErbB ReceptorsIndolesosimertinibPiperazinesProtein Kinase InhibitorsPyrimidinesTrastuzumabantibody therapyapoptosiskinase inhibitorNSCLCT790M
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.